CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Matsumoto, Lumine ^a   Takuma, Hiroshi ^b   Tamaoka, Akira ^b   Kurisaki, Hiroshi ^c   Date, Hidetoshi ^a   Tsuji, Shoji ^a   Iwata, Atsushi ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOKYO NATIONAL HOSPITAL   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE RECEPTOR; LUCIFERASE;

ADULT; AGED; ARTICLE; CELL VIABILITY; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; ENZYME ASSAY; FEMALE; GENE EXPRESSION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PUTAMEN; REGULATORY MECHANISM; SEQUENCE ANALYSIS; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; C57BL MOUSE; CADAVER; CELL STRAIN HEK293; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HELA CELL; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; CPG ISLANDS; DNA METHYLATION; DOPAMINE; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PARKINSON DISEASE; POSTMORTEM CHANGES;

EID: 78649652766     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015522     Document Type: Article

References (40)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
2. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, et al. (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
3. Mrak RE, Griffin WS (2004) Trisomy 21 and the brain. J Neuropathol Exp Neurol 63: 679-685.
4. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
5. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171.
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha- Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
7. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9: 532-544.
8. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, et al. (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296: 661-670.
9. Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, et al. (2006) Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 15: 1151-1158.
10. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
11. Drinkwater RD, Blake TJ, Morley AA, Turner DR (1989) Human lymphocytes aged in vivo have reduced levels of methylation in transcriptionally active and inactive DNA. Mutat Res 219: 29-37.
12. Fraga MF, Esteller M (2007) Epigenetics and aging: the targets and the marks. Trends Genet 23: 413-418.
13. Wilson VL, Smith RA, Ma S, Cutler RG (1987) Genomic 5-methyldeoxycytidine decreases with age. J Biol Chem 262: 9948-9951.
14. Urdinguio RG, Sanchez-Mut JV, Esteller M (2009) Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8: 1056-1072.
15. Tanji K, Imaizumi T, Yoshida H, Mori F, Yoshimoto M, et al. (2001) Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta. Neuroreport 12: 1909-1912.
16. Tanji K, Mori F, Imaizumi T, Yoshida H, Matsumiya T, et al. (2002) Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol Int 52: 572-577.
17. Clough RL, Stefanis L (2007) A novel pathway for transcriptional regulation of alpha-synuclein. Faseb J 21: 596-607.
18. Rideout HJ, Dietrich P, Savalle M, Dauer WT, Stefanis L (2003) Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. J Neurochem 84: 803-813.
19. Gomez-Santos C, Ferrer I, Reiriz J, Vinals F, Barrachina M, et al. (2002) MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 935: 32-39.
20. Gomez-Santos C, Ferrer I, Santidrian AF, Barrachina M, Gil J, et al. (2003) Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J Neurosci Res 73: 341-350.
21. Kumaki Y, Oda M, Okano M (2008) QUMA: quantification tool for methylation analysis. Nucleic Acids Res 36: W170-175.
22. Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1: 213-216.
23. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
24. Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, et al. (2003) Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum Mol Genet 12: 2625-2635.
25. Rauch T, Pfeifer GP (2005) Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 85: 1172-1180.
26. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997.
27. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alphasynuclein. Proc Natl Acad Sci U S A 105: 10907-10912.
28. Clough RL, Dermentzaki G, Stefanis L (2009) Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem 110: 1479-1490.
29. Lu A, Gupta A, Li C, Ahlborn TE, Ma Y, et al. (2001) Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences. Oncogene 20: 5173-5185.
30. Yao L, Fan P, Jiang Z, Gordon A, Mochly-Rosen D, et al. (2008) Dopamine and ethanol cause translocation of epsilonPKC associated with epsilonRACK: crosstalk between cAMP-dependent protein kinase A and protein kinase C signaling pathways. Mol Pharmacol 73: 1105-1112.
31. Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, et al. (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 30: 601-607.
32. Chiba-Falek O, Lopez GJ, Nussbaum RL (2006) Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 21: 1703-1708.
33. Dachsel JC, Lincoln SJ, Gonzalez J, Ross OA, Dickson DW, et al. (2007) The ups and downs of alpha-synuclein mRNA expression. Mov Disord 22: 293-295.
34. Barrachina M, Ferrer I (2009) DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 68: 880-891.
35. Ladd-Acosta C, Pevsner J, Sabunciyan S, Yolken RH, Webster MJ, et al. (2007) DNA methylation signatures within the human brain. Am J Hum Genet 81: 1304-1315.
36. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99: 14-20.
37. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, et al. (2000) Cterminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol 99: 296-304.
38. Terada S, Ishizu H, Haraguchi T, Takehisa Y, Tanabe Y, et al. (2000) Taunegative astrocytic star-like inclusions and coiled bodies in dementia with Lewy bodies. Acta Neuropathol 100: 464-468.
39. Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, et al. (2003) Glial involvement in diffuse Lewy body disease. Acta Neuropathol 105: 163-169.
40. Toyota M, Issa JP (1999) CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9: 349-357.